dr. mok discusses updated data with pembrolizumab in nsclc
Published 5 years ago • 1.4K plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
1:38
dr. mok discusses next steps for pembrolizumab in nsclc
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
1:28
dr. mok discusses developing lung cancer treatments
-
0:44
dr. mok on dacomitinib for first-line lung cancer treatment
-
5:00
implications for pembrolizumab in nsclc
-
1:50
dr. levy discusses pembrolizumab in nsclc
-
1:02
dr. mok on overall survival data from the alex trial in alk lung cancer
-
8:19
keynote trial data: pembrolizumab’s role in nsclc
-
1:03
dr. rizvi discusses pembrolizumab for non-small cell lung cancer
-
3:47
pembrolizumab as treatment for oligometastatic nsclc
-
2:30
dr. lopes on the keynote-042 results of frontline pembrolizumab in nsclc
-
1:15
dr. spigel on fda approval of pembrolizumab/chemo combo in nsclc
-
2:13
dr. malhotra on pembrolizumab during concurrent chemoradiation in nsclc
-
0:54
dr. bendell discusses pembrolizumab in crc
-
0:49
dr. mok on plasma testing in lung cancer
-
2:04
dr. gandhi on pembrolizumab/chemo findings in nsclc and fda approval
-
1:14
dr. herbst on long term survival with pembrolizumab in nsclc
-
1:53
dr. spigel on pembrolizumab/chemo combo in first-line nsclc
-
1:01
dr. garon on the keynote-001 study in nsclc